U.S. Markets closed
  • S&P 500

    4,274.04
    -31.16 (-0.72%)
     
  • Dow 30

    33,980.32
    -171.69 (-0.50%)
     
  • Nasdaq

    12,938.12
    -164.43 (-1.25%)
     
  • Russell 2000

    1,987.31
    -33.22 (-1.64%)
     
  • Crude Oil

    87.51
    +0.98 (+1.13%)
     
  • Gold

    1,767.80
    -5.40 (-0.30%)
     
  • Silver

    19.75
    -0.34 (-1.69%)
     
  • EUR/USD

    1.0178
    +0.0007 (+0.0712%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • Vix

    19.90
    +0.21 (+1.07%)
     
  • GBP/USD

    1.2052
    -0.0043 (-0.3519%)
     
  • USD/JPY

    135.0230
    +0.8080 (+0.6020%)
     
  • BTC-USD

    23,400.87
    -566.66 (-2.36%)
     
  • CMC Crypto 200

    557.23
    -15.58 (-2.72%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

German psychedelic startup Atai targets valuation of $2.3 bln in U.S. IPO

June 11 (Reuters) - ATAI Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday it is looking to raise as much as $214.3 million through a U.S. initial public offering, targeting a valuation of about $2.3 billion.

The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental health disorders, said it plans to sell around 14.29 million shares priced between $13 and $15 per share. (https://bit.ly/3iA5ste) (Reporting by Sohini Podder in Bengaluru; Editing by Amy Caren Daniel)